Hodgkin's Lymphoma- Pipeline Insight, 2025

This “Hodgkin’s Lymphoma- Pipeline Insight, 2025,”report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hodgkin’s Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Hodgkin’s Lymphoma Understanding

Hodgkin’s Lymphoma: Overview

Hodgkin Lymphoma also known as Hodgkin disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin’s lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years. The exact etiology of Hodgkin’s Lymphoma is not clear however, DNA mutation, and infection of Epstein-Barr virus (EBV), which causes mononucleosis can be the reason behind the development of Hodgkin’s lymphoma.

The most common symptoms of Hodgkin’s lymphoma are painless swollen lymph nodes in the neck, underarm or groin others may also include persistent fatigue, unexplained fever, drenching night sweats, sudden and unexplained weight loss, itchy skin (pruritus) swelling, pain around belly (abdominal) region and chest pain. There are four stages of this disease depending upon the diagnosis this further decides the treatment plan for the patient.

The diagnosis of the Hodgkin’s Lymphoma includes tests to identify the changes in the body of the person the tests may include blood tests that comprises of Complete blood count (CBC), Blood chemistry study, Erythrocyte sedimentation rate (ESR) secondly the imaging tests that includes CT Scans, MRI, PET scans and ultrasound apart from these lymph node biopsy is also performed to analyze the chances of the disease. Based upon the diagnosis tests done and also on identification on which stage is particular lymphoma treatment plans are designed. There are several types of treatments for Hodgkin lymphomas these treatments either kill cancer cells or keep them from dividing each treatment has different side effects. Some are as follows Chemotherapy, Radiation therapy, Immunotherapy this treatment, also called biologic therapy or biotherapy, boosts the body’s immune system. Checkpoint inhibitors are an important part of this class of treatment for Hodgkin lymphoma. Targeted therapy uses medication or other substances to attack cancer cells. Targeted therapy may include treatments such as antibody-drug conjugates. Chemotherapy with stem cell transplantation.

'Hodgkin’s Lymphoma- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hodgkin’s Lymphoma pipeline landscape is provided which includes the disease overview and Hodgkin’s Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Hodgkin’s Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hodgkin’s Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hodgkin’s Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Hodgkin’s Lymphoma.

Hodgkin’s Lymphoma Emerging Drugs Chapters

This segment of the Hodgkin’s Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hodgkin’s Lymphoma Emerging Drugs

AFM13: Affimed Therapeutics

AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is most advanced ICE® clinical program and was evaluated as monotherapy in a Phase IIB trial in patients with relapsed/refractory peripheral T cell lymphoma (REDIRECT). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. Currently it is in Phase II stage of clinical trial evaluation to treat Hodgkin’s Lymphoma.

AUR105 : Aurigene Oncology

AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications like solid tumor, non-Hodgkin lymphoma, leukemia or Hodgkin lymphoma. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I for the treatment of Hodgkin’s Lymphoma.

Hodgkin’s Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Hodgkin’s Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hodgkin’s Lymphoma

There are approx. 15+ key companies which are developing the therapies for Hodgkin’s Lymphoma. The companies which have their Hodgkin’s Lymphoma drug candidates in the most advanced stage, i.e. phase II include, Affimed Therapeutics.

Phases

Delve Insight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hodgkin’s Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Hodgkin’s Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hodgkin’s Lymphoma drugs.

Hodgkin’s Lymphoma Report Insights

• Hodgkin’s Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hodgkin’s Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hodgkin’s Lymphoma drugs?
• How many Hodgkin’s Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hodgkin’s Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hodgkin’s Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hodgkin’s Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck Sharp & Dohme LLC
• Affimed Therapeutics
• Aurigene Oncology
• Astrazeneca
• Novartis Pharmaceuticals
• Bristol-Myers Squibb
• Italfarmaco
• ADC Therapeutics

Key Products

• Favezelimab/pembrolizumab
• AFM13
• AUR105
• AZD7789
• HCD122
• Nivolumab
• ITF2357
• Camidanlumab tesirine

This product will be delivered within 1-3 business days.